XTL Biopharmaceuticals Ltd ADR (XTLB) - Total Liabilities
Based on the latest financial reports, XTL Biopharmaceuticals Ltd ADR (XTLB) has total liabilities worth $3.12 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore XTL Biopharmaceuticals Ltd ADR long-term investment allocation to see how much of total assets are deployed in long-term investments.
XTL Biopharmaceuticals Ltd ADR - Total Liabilities Trend (2002–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of XTL Biopharmaceuticals Ltd ADR.
XTL Biopharmaceuticals Ltd ADR Competitors by Total Liabilities
The table below lists competitors of XTL Biopharmaceuticals Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
North Arrow Minerals Inc
V:NAR
|
Canada | CA$268.84K |
|
Skye Bioscience, Inc. Common Stock
NASDAQ:SKYE
|
USA | $11.53 Million |
|
Nuvotec
KQ:060260
|
Korea | ₩32.17 Billion |
|
BRADDA HEAD LITHIUM O.N.
F:8CD1
|
Germany | €73.64K |
|
Visgeneer
TWO:4197
|
Taiwan | NT$130.36 Million |
|
ChargePanel AB
ST:CHARGE
|
Sweden | Skr8.62 Million |
|
Winfarm
PA:ALWF
|
France | €57.66 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down XTL Biopharmaceuticals Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of XTL Biopharmaceuticals Ltd ADR to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XTL Biopharmaceuticals Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XTL Biopharmaceuticals Ltd ADR (2002–2024)
The table below shows the annual total liabilities of XTL Biopharmaceuticals Ltd ADR from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.12 Million | +1412.14% |
| 2023-12-31 | $206.00K | +10.16% |
| 2022-12-31 | $187.00K | -85.45% |
| 2021-12-31 | $1.28 Million | +405.91% |
| 2020-12-31 | $254.00K | +9.48% |
| 2019-12-31 | $232.00K | -8.30% |
| 2018-12-31 | $253.00K | -91.47% |
| 2017-12-31 | $2.97 Million | +799.09% |
| 2016-12-31 | $330.00K | -24.31% |
| 2015-12-31 | $436.00K | -54.82% |
| 2014-12-31 | $965.00K | -21.54% |
| 2013-12-31 | $1.23 Million | -25.99% |
| 2012-12-31 | $1.66 Million | +164.23% |
| 2011-12-31 | $629.00K | -34.68% |
| 2010-12-31 | $963.00K | +36.02% |
| 2009-12-31 | $708.00K | -64.67% |
| 2008-12-31 | $2.00 Million | -63.98% |
| 2007-12-31 | $5.56 Million | +34.37% |
| 2006-12-31 | $4.14 Million | +6.18% |
| 2005-12-31 | $3.90 Million | -35.25% |
| 2004-12-31 | $6.02 Million | +41.86% |
| 2003-12-31 | $4.25 Million | +18.15% |
| 2002-12-31 | $3.59 Million | -- |
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more